No label defined (Q32094)

From lgbtDB
Revision as of 20:39, 14 November 2024 by Superraptor (talk | contribs) (‎Created a new Item)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
No description defined
  • Oral HPV infection clearance and acquisition after nonavalent vaccination in men who have sex with men and transgender women: a prospective analysis.
Language Label Description Also known as
English
No label defined
No description defined
  • Oral HPV infection clearance and acquisition after nonavalent vaccination in men who have sex with men and transgender women: a prospective analysis.

Statements

Oral HPV infection clearance and acquisition after nonavalent vaccination in men who have sex with men and transgender women: a prospective analysis. (English)
1 reference
Oral HPV infection is the main risk factor for the development of oropharyngeal carcinoma. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
Men who have sex with men (MSM), especially if living with HIV (PLWH), are at increased risk of infection and consequently of cancer development. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
Aim of this study is to evaluate the impact of nonavalent vaccine on oral HPV infection in a cohort of MSM and transgender women (TGW). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
This prospective study included all MSM and TGW who started nonavalent HPV vaccination from May 2019 to September 2021. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
Oral rinse was collected before each vaccine administration and after six months of follow up. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
Descriptive statistics were used. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
Kaplan Meier probability curves and Cox regression models for HPV acquisition and clearance were calculated. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
The analysis included 211 individuals (202 MSM and 9 TGW). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
PLWH were 138 (65.4%). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
Baseline oral rinse was positive in 30 subjects (14.2%). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
Positivity rate did not change over time (p = 0.742), even when restricting the analysis only to high-risk genotypes (p = 0.575) and to genotypes covered by vaccine (p = 0.894). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
The risk to acquire HPV infection was 12.8% at one year and 33.4% at two years after vaccination. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
The probability to clear the infection was 67.6% at one year and 87.9% at two years. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
HIV infection had no impact on vaccine efficacy. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
Age above 45 years was the only factor associated to HPV acquisition (aHR 4.06, 95% CI 1.03-15.98, p = 0.045). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
Prevalence of oral HPV infection was higher in PLWH, but HIV had no impact on viral clearance or acquisition after vaccination. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
1 reference
September 2024
1 reference
September 2024
1 reference
1 reference
Andrea Marco (English)
Tamburini (English)
1 reference
43
1 reference
9
1 reference
1847-1854
1 reference
1847
1 reference
1854
1 reference